News

NICE backs NHS care for severe allergic asthma

19-Jun-07

Patients with severe allergic asthma could be treated with omalizumab on the NHS, according to NICE.
A draft technology appraisal states that omalizumab can be given to patients with a clinical confirmation of asthma mediated by immunoglobulin E.

Other prerequisites include at least two exacerbations of asthma leading to hospital admission in the past year, a full trial and compliance with treatments outlined in the British Thoracic Society/ Scottish Intercollegiate Guideline Net-work guidelines, and that the patient does not smoke.

If a patient complies with this, they could be referred to a specialist for omalizumab treatment, which is injected subcutaneously every two to four weeks.

This could lead to annual costs as high as £15,400 per patient. But NICE says patients should be taken off the drug at 16 weeks if they show an inadequate response.

Response would be assessed by looking at improvements in daily symptoms and peak expiratory flow rate, reduced need for systemic corticosteroids and fewer unplanned consultations for asthma.

The document is open for consultation until 3 July.

What do you think? Comment below or email healthcare.republic@haymarket.com  

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Registrar

Career paths - Working abroad in a rural practice

Dr Kingsley Poole describes the differences he experienced working at a remote practice in New Zeala... Read more

Professional development - Honing your presentation skills

Most people feel nervous facing an audience, but practice will make it easier, says Dr Kevin Brown. Read more

Journals club - HPV vaccine

Curriculum statement 5. Healthy people: promoting health and preventing disease. Read more

Show all articles

 

Latest Clinical Articles

Clinical Review - Renal colic

Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more

Clinical Review - Stroke

By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more

Sjogren's syndrome

Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more

Show all clinical articles

MIMS Product News

New drug - Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more

New drug - Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more

Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more

Jobs

 

Job of the Week